{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:11:16Z","timestamp":1790813476429,"version":"4.1.0"},"reference-count":64,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Cancer Foundation of North Texas (CRFNT)","award":["97313"],"award-info":[{"award-number":["97313"]}]},{"name":"Cancer Foundation of North Texas (CRFNT)","award":["77313b"],"award-info":[{"award-number":["77313b"]}]},{"name":"Cancer Foundation of North Texas (CRFNT)","award":["RI6062"],"award-info":[{"award-number":["RI6062"]}]},{"name":"Leukemia Texas Inc.","award":["97313"],"award-info":[{"award-number":["97313"]}]},{"name":"Leukemia Texas Inc.","award":["77313b"],"award-info":[{"award-number":["77313b"]}]},{"name":"Leukemia Texas Inc.","award":["RI6062"],"award-info":[{"award-number":["RI6062"]}]},{"name":"Institute for Cancer Research, UNTHSC","award":["97313"],"award-info":[{"award-number":["97313"]}]},{"name":"Institute for Cancer Research, UNTHSC","award":["77313b"],"award-info":[{"award-number":["77313b"]}]},{"name":"Institute for Cancer Research, UNTHSC","award":["RI6062"],"award-info":[{"award-number":["RI6062"]}]},{"name":"Team Connor Childhood Cancer Foundation","award":["97313"],"award-info":[{"award-number":["97313"]}]},{"name":"Team Connor Childhood Cancer Foundation","award":["77313b"],"award-info":[{"award-number":["77313b"]}]},{"name":"Team Connor Childhood Cancer Foundation","award":["RI6062"],"award-info":[{"award-number":["RI6062"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Acute lymphoblastic leukemia (ALL) represents the most common pediatric cancer. Most patients (85%) develop B-cell ALL; however, T-cell ALL tends to be more aggressive. We have previously identified 2B4 (SLAMF4), CS1 (SLAMF7) and LLT1 (CLEC2D) that can activate or inhibit NK cells upon the interaction with their ligands. In this study, the expression of 2B4, CS1, LLT1, NKp30 and NKp46 was determined. The expression profiles of these immune receptors were analyzed in the peripheral blood mononuclear cells of B-ALL and T-ALL subjects by single-cell RNA sequencing data obtained from the St. Jude PeCan data portal that showed increased expression of LLT1 in B-ALL and T-ALL subjects. Whole blood was collected from 42 pediatric ALL subjects at diagnosis and post-induction chemotherapy and 20 healthy subjects, and expression was determined at the mRNA and cell surface protein level. A significant increase in cell surface LLT1 expression in T cells, monocytes and NK cells was observed. Increased expression of CS1 and NKp46 was observed on monocytes of ALL subjects at diagnosis. A decrease of LLT1, 2B4, CS1 and NKp46 on T cells of ALL subjects was also observed post-induction chemotherapy. Furthermore, mRNA data showed altered expression of receptors in ALL subjects pre- and post-induction chemotherapy treatment. The results indicate that the differential expression of the receptors\/ligand may play a role in the T-cell- and NK-cell-mediated immune surveillance of pediatric ALL.<\/jats:p>","DOI":"10.3390\/ijms24043860","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T03:09:21Z","timestamp":1676430561000},"page":"3860","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Differential Expression of LLT1, SLAM Receptors CS1 and 2B4 and NCR Receptors NKp46 and NKp30 in Pediatric Acute Lymphoblastic Leukemia (ALL)"],"prefix":"10.3390","volume":"24","author":[{"given":"Sheila B.","family":"Powers","sequence":"first","affiliation":[{"name":"Department of Microbiology, Immunology and Genetics, University of North Texas Health Science Center, Fort Worth, TX 76107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nourhan G.","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Genetics, University of North Texas Health Science Center, Fort Worth, TX 76107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roslin","family":"Jose","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Genetics, University of North Texas Health Science Center, Fort Worth, TX 76107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Brezgiel","sequence":"additional","affiliation":[{"name":"Texas College of Osteopathic Medicine, University of North Texas Health Science Center, Fort Worth, TX 76107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhash","family":"Aryal","sequence":"additional","affiliation":[{"name":"School of Nursing, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Paul","family":"Bowman","sequence":"additional","affiliation":[{"name":"Texas College of Osteopathic Medicine, University of North Texas Health Science Center, Fort Worth, TX 76107, USA"},{"name":"Cook Children\u2019s Medical Center, 801 7th Avenue, Fort Worth, TX 76104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Porunelloor A.","family":"Mathew","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Genetics, University of North Texas Health Science Center, Fort Worth, TX 76107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5784-224X","authenticated-orcid":false,"given":"Stephen O.","family":"Mathew","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Genetics, University of North Texas Health Science Center, Fort Worth, TX 76107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.beha.2017.07.004","article-title":"Acute lymphoblastic leukemia (ALL)","volume":"30","author":"Advani","year":"2017","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1200\/JOP.18.00271","article-title":"Acute Lymphoblastic Leukemia in the Older Adult","volume":"15","author":"Aldoss","year":"2019","journal-title":"J. Oncol. Pract."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/10428194.2017.1326597","article-title":"Managing CNS disease in adults with acute lymphoblastic leukemia","volume":"59","author":"Larson","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Carreras, E., Dufour, C., Mohty, M., and Kroger, N. (2019). The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies, Springer. [7th ed.].","DOI":"10.1007\/978-3-030-02278-5"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: A comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0140-6736(12)62187-4","article-title":"Acute lymphoblastic leukaemia","volume":"381","author":"Inaba","year":"2013","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration","volume":"33","author":"Pui","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40272-017-0268-7","article-title":"Agents in Development for Childhood Acute Lymphoblastic Leukemia","volume":"20","author":"Maloney","year":"2018","journal-title":"Paediatr. Drugs"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"103492","DOI":"10.1016\/j.critrevonc.2021.103492","article-title":"Bone health in glucocorticoid-treated childhood acute lymphoblastic leukemia","volume":"168","author":"Velentza","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.seminhematol.2008.09.007","article-title":"Treatment of childhood acute lymphoblastic leukemia","volume":"46","author":"Stanulla","year":"2009","journal-title":"Semin. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","article-title":"Pediatric acute lymphoblastic leukemia","volume":"105","author":"Inaba","year":"2020","journal-title":"Haematologica"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/1055-9965.EPI-21-1388","article-title":"Long-Term Outcomes among Adolescent and Young Adult Survivors of Acute Leukemia: A Surveillance, Epidemiology, and End Results Analysis","volume":"31","author":"Berkman","year":"2022","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1182\/blood.2019004043","article-title":"How I treat relapsed acute lymphoblastic leukemia in the pediatric population","volume":"136","author":"Hunger","year":"2020","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/MOP.0000000000000293","article-title":"Therapies on the horizon for childhood acute lymphoblastic leukemia","volume":"28","author":"Carroll","year":"2016","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1200\/EDBK_280175","article-title":"Recent Advances in Managing Acute Lymphoblastic Leukemia","volume":"40","author":"DeAngelo","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/1078155217713363","article-title":"A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia","volume":"24","author":"DasGupta","year":"2018","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1080\/10428194.2021.1964022","article-title":"Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults","volume":"62","author":"Kimble","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.exphem.2004.11.006","article-title":"Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia","volume":"33","author":"Romanski","year":"2005","journal-title":"Exp. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-020-01014-w","article-title":"NK cell-based cancer immunotherapy: From basic biology to clinical development","volume":"14","author":"Liu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.3389\/fimmu.2019.02357","article-title":"Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells","volume":"10","author":"Carlsten","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1002\/ijc.32269","article-title":"Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth","volume":"145","author":"Oelsner","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e00169-17","DOI":"10.1128\/JVI.00169-17","article-title":"Redefining Memory: Building the Case for Adaptive NK Cells","volume":"91","author":"Paust","year":"2017","journal-title":"J. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1158\/2326-6066.CIR-17-0550","article-title":"CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells","volume":"6","author":"Pahl","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1158\/2326-6066.CIR-20-1002","article-title":"A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy","volume":"9","author":"Shrestha","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/2159-8290.CD-20-0655","article-title":"Tumor-Infiltrating Natural Killer Cells","volume":"11","author":"Cozar","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.3389\/fimmu.2019.01999","article-title":"NK Cell Dysfunction and Checkpoint Immunotherapy","volume":"10","author":"Bi","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002510050679","article-title":"Cloning of a new lectin-like receptor expressed on human NK cells","volume":"50","author":"Boles","year":"1999","journal-title":"Immunogenetics"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s002510000274","article-title":"Molecular cloning of CS1, a novel human natural killer cell receptor belonging to the CD2 subset of the immunoglobulin superfamily","volume":"52","author":"Boles","year":"2001","journal-title":"Immunogenetics"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1034\/j.1399-0039.1999.540103.x","article-title":"Molecular characterization of a novel human natural killer cell receptor homologous to mouse 2B4","volume":"54","author":"Boles","year":"1999","journal-title":"Tissue Antigens"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1365-2249.2010.04116.x","article-title":"Altered expression of signalling lymphocyte activation molecule (SLAM) family receptors CS1 (CD319) and 2B4 (CD244) in patients with systemic lupus erythematosus","volume":"160","author":"Kim","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"68650","DOI":"10.18632\/oncotarget.11896","article-title":"Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer cells inhibits NK cell-mediated killing through LLT1-NKRP1A (CD161) interaction","volume":"7","author":"Mathew","year":"2016","journal-title":"Oncotarget"},{"key":"ref_33","first-page":"1050","article-title":"Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells","volume":"8","author":"Marrufo","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"ref_34","first-page":"1637","article-title":"CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma","volume":"7","author":"Malaer","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Buller, C.W., Mathew, P.A., and Mathew, S.O. (2020). Roles of NK Cell Receptors 2B4 (CD244), CS1 (CD319), and LLT1 (CLEC2D) in Cancer. Cancers, 12.","DOI":"10.3390\/cancers12071755"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.clim.2018.10.009","article-title":"2B4 (CD244, SLAMF4) and CS1 (CD319, SLAMF7) in systemic lupus erythematosus and cancer","volume":"204","author":"Malaer","year":"2019","journal-title":"Clin. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3389\/fimmu.2019.00909","article-title":"The Natural Cytotoxicity Receptors in Health and Disease","volume":"10","author":"Barrow","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1021\/pr800747c","article-title":"Natural cytotoxicity receptors NKp30, NKp44 and NKp46 bind to different heparan sulfate\/heparin sequences","volume":"8","author":"Hecht","year":"2009","journal-title":"J. Proteome Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10522-015-9581-0","article-title":"Expression of NKp30, NKp46 and DNAM-1 activating receptors on resting and IL-2 activated NK cells from healthy donors according to CMV-serostatus and age","volume":"16","author":"Campos","year":"2015","journal-title":"Biogerontology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/leu.2008.251","article-title":"Factors influencing survival after relapse from acute lymphoblastic leukemia: A Children\u2019s Oncology Group study","volume":"22","author":"Nguyen","year":"2008","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.2009.25.1983","article-title":"Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: Results of trial ALL-REZ BFM 90","volume":"28","author":"Tallen","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3324\/haematol.2015.131680","article-title":"Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: Prognostic factors, treatment and outcome","volume":"101","author":"Oskarsson","year":"2016","journal-title":"Haematologica"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1586\/17474086.2015.978281","article-title":"Risk factors for relapse in childhood acute lymphoblastic leukemia: Prediction and prevention","volume":"8","author":"Ceppi","year":"2015","journal-title":"Expert Rev. Hematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s11684-020-0759-8","article-title":"Precision medicine in acute lymphoblastic leukemia","volume":"14","author":"Pui","year":"2020","journal-title":"Front. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood.2021013648","article-title":"Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia","volume":"140","author":"Maciocia","year":"2022","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17474086.2017.1262757","article-title":"Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma","volume":"10","author":"Kadia","year":"2017","journal-title":"Expert Rev. Hematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3389\/fimmu.2015.00601","article-title":"Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy","volume":"6","author":"Chester","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"7796","DOI":"10.4049\/jimmunol.175.12.7796","article-title":"Cutting edge: Lectin-like transcript-1 is a ligand for the inhibitory human NKR-P1A receptor","volume":"175","author":"Rosen","year":"2005","journal-title":"J. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-06-4783","article-title":"Malignant glioma cells counteract antitumor immune responses through expression of lectin-like transcript-1","volume":"67","author":"Roth","year":"2007","journal-title":"Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Sanchez-Canteli, M., Hermida-Prado, F., Sordo-Bahamonde, C., Montoro-Jimenez, I., Pozo-Agundo, E., Allonca, E., Vallina-Alvarez, A., Alvarez-Marcos, C., Gonzalez, S., and Garcia-Pedrero, J.M. (2020). Lectin-Like Transcript 1 (LLT1) Checkpoint: A Novel Independent Prognostic Factor in HPV-Negative Oropharyngeal Squamous Cell Carcinoma. Biomedicines, 8.","DOI":"10.3390\/biomedicines8120535"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"6613","DOI":"10.21873\/anticanres.14686","article-title":"Role of LLT1 and PCNA as Natural Killer Cell Immune Evasion Strategies of HCT 116 Cells","volume":"40","author":"Malaer","year":"2020","journal-title":"Anticancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e1423184","DOI":"10.1080\/2162402X.2017.1423184","article-title":"Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome","volume":"7","author":"Braud","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e1026503","DOI":"10.1080\/2162402X.2015.1026503","article-title":"Lectin-like transcript 1 is a marker of germinal center-derived B-cell non-Hodgkin\u2019s lymphomas dampening natural killer cell functions","volume":"4","author":"Germain","year":"2015","journal-title":"Oncoimmunology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"847576","DOI":"10.3389\/fimmu.2022.847576","article-title":"LLT1-CD161 Interaction in Cancer: Promises and Challenges","volume":"13","author":"Braud","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3389\/fimmu.2017.00760","article-title":"NK Cell Exhaustion","volume":"8","author":"Bi","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fcimb.2020.00049","article-title":"Characterizing the Dysfunctional NK Cell: Assessing the Clinical Relevance of Exhaustion, Anergy, and Senescence","volume":"10","author":"Judge","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00011-013-0632-1","article-title":"CS1 (SLAMF7) inhibits production of proinflammatory cytokines by activated monocytes","volume":"62","author":"Kim","year":"2013","journal-title":"Inflamm. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"228","DOI":"10.4049\/jimmunol.1800847","article-title":"SLAMF7 Is a Critical Negative Regulator of IFN-alpha-Mediated CXCL10 Production in Chronic HIV Infection","volume":"202","author":"Pepelyayeva","year":"2019","journal-title":"J. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1182\/blood.2019000051","article-title":"Increased SLAMF7(high) monocytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab","volume":"134","author":"Maekawa","year":"2019","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Chalan, P., Bijzet, J., Huitema, M.G., Kroesen, B.J., Brouwer, E., and Boots, A.M. (2015). Expression of Lectin-Like Transcript 1, the Ligand for CD161, in Rheumatoid Arthritis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0132436"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Schlaphoff, V., Lunemann, S., Suneetha, P.V., Jaroszewicz, J., Grabowski, J., Dietz, J., Helfritz, F., Bektas, H., Sarrazin, C., and Manns, M.P. (2011). Dual function of the NK cell receptor 2B4 (CD244) in the regulation of HCV-specific CD8+ T cells. PLoS Pathog., 7.","DOI":"10.1371\/journal.ppat.1002045"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e1274478","DOI":"10.1080\/2162402X.2016.1274478","article-title":"IL-12, IL-15, and IL-18 pre-activated NK cells target resistant T cell acute lymphoblastic leukemia and delay leukemia development in vivo","volume":"6","author":"Boieri","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Garcia-Iglesias, T., Del Toro-Arreola, A., Albarran-Somoza, B., Del Toro-Arreola, S., Sanchez-Hernandez, P.E., Ramirez-Duenas, M.G., Balderas-Pena, L.M., Bravo-Cuellar, A., Ortiz-Lazareno, P.C., and Daneri-Navarro, A. (2009). Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. BMC Cancer, 9.","DOI":"10.1186\/1471-2407-9-186"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/4\/3860\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:35:44Z","timestamp":1760121344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/4\/3860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,15]]},"references-count":64,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["ijms24043860"],"URL":"https:\/\/doi.org\/10.3390\/ijms24043860","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,15]]}}}